2. Membrane Transporter/Ion Channel Apoptosis
  3. P2X Receptor Apoptosis
  4. Minodronic acid hydrate

Minodronic acid hydrate  (Synonyms: YM-529 hydrate)

Cat. No.: HY-16322A Purity: 99.67%
COA
SDS
Handling Instructions Technical Support

Minodronic acid (YM-529) hydrate is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid hydrate induces tumor cell apoptosis and inhibits cell growth. Minodronic acid hydrate also suppresses bone resorption. Minodronic acid hydrate can be used in research related to osteoporosis and cancer.

For research use only. We do not sell to patients.

Minodronic acid hydrate

Minodronic acid hydrate Chemical Structure

CAS No. : 155648-60-5

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Minodronic acid hydrate:

Minodronic acid hydrate Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Minodronic acid hydrate

View All P2X Receptor Isoform Specific Products:

View All Isoforms
P2X1 Receptor P2X2 Receptor P2X3 Receptor P2X4 Receptor P2X7 Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Minodronic acid (YM-529) hydrate is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid hydrate induces tumor cell apoptosis and inhibits cell growth. Minodronic acid hydrate also suppresses bone resorption. Minodronic acid hydrate can be used in research related to osteoporosis and cancer[1][2].

In Vitro

Minodronic acid (5-100 μM; 72 h) hydrate inhibits the proliferation of human bladder cancer cell lines 253J, 5637, RT4, RT112, TCCSUP, KU-7 and UM-UC-3 in a dose-dependent manner[1].
Minodronic acid (30 μM; 48 h) hydrate induces apoptosis in human bladder cancer cells[1].
Minodronic acid (0.25-2.0 × IC50; 72 h) hydrate exhibits synergistic or additive antiproliferative effects when combined with Cisplatin (HY-17394) or Paclitaxel (HY-B0015) in human bladder cancer cell lines KU-7, RT112 and UM-UC-3[1].
Minodronic acid (0.1-1 μM; 3 days) hydrate potently inhibits osteoclast-mediated bone resorption in rabbits and induces dose-dependent morphological changes; at 1 μM, it almost completely inhibits bone resorption and causes osteoclast detachment, while at 0.1 μM, it only exerts partial inhibitory effects accompanied by the disappearance of the ruffled border[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Minodronic acid hydrate Related Antibodies

Cell Proliferation Assay[1]

Cell Line: 253J, 5637, RT4, RT112, TCCSUP, KU-7, UM-UC-3 human bladder cancer cells
Concentration: 5, 10, 25, 50, 100 μM
Incubation Time: 72 h
Result: Inhibited cell growth in a dose-dependent manner.
Achieved IC50 values of 12.2 μM (253J), 7.1 μM (5637), 12.2 μM (RT4), 15.4 μM (RT112), 21.8 μM (TCCSUP), 24.8 μM (KU-7), and 20.8 μM (UM-UC-3).
In Vivo

Minodronic acid (80 μg/kg; subcutaneous injection; once weekly; for 3 consecutive weeks) hydrate significantly inhibits the growth of bladder cancer bone metastases in BALB/c nu/nu mice without causing adverse effects[1].
Minodronic acid (30-100 μM; transurethral administration; 5 days) hydrate inhibits the growth of orthotopic bladder cancer in SCID mice [1].
Minodronic acid (0.05-5 mg/kg; subcutaneous injection; single administration) hydrate accumulates in the calcified and ossified regions of rat bones, concentrates in osteoclast-containing bone tissue sites, and exhibits dose-dependent bone tissue localization characteristics[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nu/nu (female, 6-8 weeks old, intracardiac injection of 1×106 UM-UC-3^LUC cells to induce bone metastases)[1]
Dosage: 80 μg/kg
Administration: s.c.; once weekly; 3 weeks
Result: Significantly reduced growth of bone metastatic lesions compared to untreated mice.
Did not significantly inhibit visceral metastases.
Showed no significant differences in body weight or serum components (AST, ALT, LDH, TP, BUN, Cre, Ca) compared to untreated mice.
Animal Model: BALB/c nu/nu (female, 6-8 weeks old, intracardiac injection of 1×106 UM-UC-3^LUC cells to induce bone metastases)[1]
Dosage: 80 μg/kg
Administration: s.c.; once weekly; 3 weeks
Result: Significantly reduced growth of bone metastatic lesions compared to untreated mice.
Did not significantly inhibit visceral metastases.
Showed no significant differences in body weight or serum components (AST, ALT, LDH, TP, BUN, Cre, Ca) compared to untreated mice.
Animal Model: SCID (female, 6-8 weeks old, orthotopic implantation of 2×106 UM-UC-3^LUC cells into bladder)[1]
Dosage: 30 μM; 100 μM
Administration: transurethral; daily for 5 consecutive days (days 5-9)
Result: Significantly suppressed orthotopic bladder tumor growth, no significant systemic toxicity was observed, and occasional deaths were attributed to mechanical renal injury rather than drug-related toxicity.
Clinical Trial
Molecular Weight

340.16

Formula

C9H14N2O8P2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2C=CC=CN21.O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

1 M NaOH : ≥ 100 mg/mL (293.98 mM)

H2O : 20 mg/mL (58.80 mM; ultrasonic and adjust pH to 9 with 1 M NaOH)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9398 mL 14.6990 mL 29.3979 mL
5 mM 0.5880 mL 2.9398 mL 5.8796 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / 1 M NaOH 1 mM 2.9398 mL 14.6990 mL 29.3979 mL 73.4948 mL
5 mM 0.5880 mL 2.9398 mL 5.8796 mL 14.6990 mL
10 mM 0.2940 mL 1.4699 mL 2.9398 mL 7.3495 mL
15 mM 0.1960 mL 0.9799 mL 1.9599 mL 4.8997 mL
20 mM 0.1470 mL 0.7349 mL 1.4699 mL 3.6747 mL
25 mM 0.1176 mL 0.5880 mL 1.1759 mL 2.9398 mL
30 mM 0.0980 mL 0.4900 mL 0.9799 mL 2.4498 mL
40 mM 0.0735 mL 0.3675 mL 0.7349 mL 1.8374 mL
50 mM 0.0588 mL 0.2940 mL 0.5880 mL 1.4699 mL
1 M NaOH 60 mM 0.0490 mL 0.2450 mL 0.4900 mL 1.2249 mL
80 mM 0.0367 mL 0.1837 mL 0.3675 mL 0.9187 mL
100 mM 0.0294 mL 0.1470 mL 0.2940 mL 0.7349 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Minodronic acid hydrate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Minodronic acid155648-60-5YM-529YM529YM 529P2X ReceptorApoptosisP2XRsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Minodronic acid hydrate
Cat. No.:
HY-16322A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (584 KB) Français - FR (584 KB) Deutsch - DE (584 KB) Norwegian - NO (584 KB) Español - ES (584 KB) Swedish - SV (584 KB) Italian - IT (584 KB) Korean - KR (584 KB) Portuguese - PT (584 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.